With A Potential Blockbuster Drug, And Ripe For Acquisition, This Biotech Stock Could Be A Big Winner

With a potential $5+ billion drug that could ultimately be used against dozens of diseases, the clinical-stage biotech company discussed in today’s article “is a ripe acquisition target, and when that acquisition comes, it will go for a steep price,” according to one stock picker. For more on this biotech stock with the potential to be a big winner, CLICK HERE.